Inhibition of influenza A virus infection by Galectin-9

Tomoe Hattori, Tomohiro Arikawa, Yoichiro Fujioka, Junki Maruyama, Yousuke Nakayama, Yusuke Ohba, Toshiro Niki, Tadaaki Miyazaki, Mitsuomi Hirashima, Hiroshi Kida

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Galectin-9 (Gal-9) inhibited the infection of H1N1, H3N2 and H5N1 influenza A viruses in vitro and in vivo. Fifty percent effective doses (ED50) of Gal-9 were 0.1-0.5 μM depending on virus strains in the plaque reduction assay. Gal-9 but not Gal-1 bound to the virus particles of A/Puerto Rico/8/34 (H1N1) (PR/8), resulting in inhibition of virus attachment to the host cells. Lactose but not sucrose inhibited the binding of Gal-9 to the viruses. Endogenous Gal-9 expression was detected and increased with the course of infection with influenza A viruses in mice. Fifty percent of Gal-9-transgenic mice survived after the challenge with PR/8, while all of the wild-type mice died. Gal-9 treatment of mice affected diminishing influenza virus replication in the lungs, body weight loss and the expression level of inflammatory cytokines. Combined administration of Gal-9 and oseltamivir was more effective than the use of single compound in mouse model. The present results indicate that Gal-9 is a candidate compound for influenza A virus infection therapy.

Original languageEnglish (US)
Pages (from-to)5-18
Number of pages14
JournalJapanese Journal of Veterinary Research
Volume61
Issue number1-2
StatePublished - Jul 31 2013
Externally publishedYes

Fingerprint

Galectins
Influenza A virus
Virus Diseases
mice
infection
viruses
Puerto Rico
Orthomyxoviridae
virus replication
virion
lactose
cytokines
weight loss
animal models
lungs
genetically modified organisms
sucrose
H5N1 Subtype Influenza A Virus
Viruses
Oseltamivir

Keywords

  • Gal-9
  • Influenza A virus
  • Inhibition of viral growth

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Hattori, T., Arikawa, T., Fujioka, Y., Maruyama, J., Nakayama, Y., Ohba, Y., ... Kida, H. (2013). Inhibition of influenza A virus infection by Galectin-9. Japanese Journal of Veterinary Research, 61(1-2), 5-18.

Inhibition of influenza A virus infection by Galectin-9. / Hattori, Tomoe; Arikawa, Tomohiro; Fujioka, Yoichiro; Maruyama, Junki; Nakayama, Yousuke; Ohba, Yusuke; Niki, Toshiro; Miyazaki, Tadaaki; Hirashima, Mitsuomi; Kida, Hiroshi.

In: Japanese Journal of Veterinary Research, Vol. 61, No. 1-2, 31.07.2013, p. 5-18.

Research output: Contribution to journalArticle

Hattori, T, Arikawa, T, Fujioka, Y, Maruyama, J, Nakayama, Y, Ohba, Y, Niki, T, Miyazaki, T, Hirashima, M & Kida, H 2013, 'Inhibition of influenza A virus infection by Galectin-9', Japanese Journal of Veterinary Research, vol. 61, no. 1-2, pp. 5-18.
Hattori T, Arikawa T, Fujioka Y, Maruyama J, Nakayama Y, Ohba Y et al. Inhibition of influenza A virus infection by Galectin-9. Japanese Journal of Veterinary Research. 2013 Jul 31;61(1-2):5-18.
Hattori, Tomoe ; Arikawa, Tomohiro ; Fujioka, Yoichiro ; Maruyama, Junki ; Nakayama, Yousuke ; Ohba, Yusuke ; Niki, Toshiro ; Miyazaki, Tadaaki ; Hirashima, Mitsuomi ; Kida, Hiroshi. / Inhibition of influenza A virus infection by Galectin-9. In: Japanese Journal of Veterinary Research. 2013 ; Vol. 61, No. 1-2. pp. 5-18.
@article{28eead46193b451a826052153b3136cc,
title = "Inhibition of influenza A virus infection by Galectin-9",
abstract = "Galectin-9 (Gal-9) inhibited the infection of H1N1, H3N2 and H5N1 influenza A viruses in vitro and in vivo. Fifty percent effective doses (ED50) of Gal-9 were 0.1-0.5 μM depending on virus strains in the plaque reduction assay. Gal-9 but not Gal-1 bound to the virus particles of A/Puerto Rico/8/34 (H1N1) (PR/8), resulting in inhibition of virus attachment to the host cells. Lactose but not sucrose inhibited the binding of Gal-9 to the viruses. Endogenous Gal-9 expression was detected and increased with the course of infection with influenza A viruses in mice. Fifty percent of Gal-9-transgenic mice survived after the challenge with PR/8, while all of the wild-type mice died. Gal-9 treatment of mice affected diminishing influenza virus replication in the lungs, body weight loss and the expression level of inflammatory cytokines. Combined administration of Gal-9 and oseltamivir was more effective than the use of single compound in mouse model. The present results indicate that Gal-9 is a candidate compound for influenza A virus infection therapy.",
keywords = "Gal-9, Influenza A virus, Inhibition of viral growth",
author = "Tomoe Hattori and Tomohiro Arikawa and Yoichiro Fujioka and Junki Maruyama and Yousuke Nakayama and Yusuke Ohba and Toshiro Niki and Tadaaki Miyazaki and Mitsuomi Hirashima and Hiroshi Kida",
year = "2013",
month = "7",
day = "31",
language = "English (US)",
volume = "61",
pages = "5--18",
journal = "Japanese Journal of Veterinary Research",
issn = "0047-1917",
publisher = "Hokkaido University",
number = "1-2",

}

TY - JOUR

T1 - Inhibition of influenza A virus infection by Galectin-9

AU - Hattori, Tomoe

AU - Arikawa, Tomohiro

AU - Fujioka, Yoichiro

AU - Maruyama, Junki

AU - Nakayama, Yousuke

AU - Ohba, Yusuke

AU - Niki, Toshiro

AU - Miyazaki, Tadaaki

AU - Hirashima, Mitsuomi

AU - Kida, Hiroshi

PY - 2013/7/31

Y1 - 2013/7/31

N2 - Galectin-9 (Gal-9) inhibited the infection of H1N1, H3N2 and H5N1 influenza A viruses in vitro and in vivo. Fifty percent effective doses (ED50) of Gal-9 were 0.1-0.5 μM depending on virus strains in the plaque reduction assay. Gal-9 but not Gal-1 bound to the virus particles of A/Puerto Rico/8/34 (H1N1) (PR/8), resulting in inhibition of virus attachment to the host cells. Lactose but not sucrose inhibited the binding of Gal-9 to the viruses. Endogenous Gal-9 expression was detected and increased with the course of infection with influenza A viruses in mice. Fifty percent of Gal-9-transgenic mice survived after the challenge with PR/8, while all of the wild-type mice died. Gal-9 treatment of mice affected diminishing influenza virus replication in the lungs, body weight loss and the expression level of inflammatory cytokines. Combined administration of Gal-9 and oseltamivir was more effective than the use of single compound in mouse model. The present results indicate that Gal-9 is a candidate compound for influenza A virus infection therapy.

AB - Galectin-9 (Gal-9) inhibited the infection of H1N1, H3N2 and H5N1 influenza A viruses in vitro and in vivo. Fifty percent effective doses (ED50) of Gal-9 were 0.1-0.5 μM depending on virus strains in the plaque reduction assay. Gal-9 but not Gal-1 bound to the virus particles of A/Puerto Rico/8/34 (H1N1) (PR/8), resulting in inhibition of virus attachment to the host cells. Lactose but not sucrose inhibited the binding of Gal-9 to the viruses. Endogenous Gal-9 expression was detected and increased with the course of infection with influenza A viruses in mice. Fifty percent of Gal-9-transgenic mice survived after the challenge with PR/8, while all of the wild-type mice died. Gal-9 treatment of mice affected diminishing influenza virus replication in the lungs, body weight loss and the expression level of inflammatory cytokines. Combined administration of Gal-9 and oseltamivir was more effective than the use of single compound in mouse model. The present results indicate that Gal-9 is a candidate compound for influenza A virus infection therapy.

KW - Gal-9

KW - Influenza A virus

KW - Inhibition of viral growth

UR - http://www.scopus.com/inward/record.url?scp=84880667353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880667353&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84880667353

VL - 61

SP - 5

EP - 18

JO - Japanese Journal of Veterinary Research

JF - Japanese Journal of Veterinary Research

SN - 0047-1917

IS - 1-2

ER -